Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 30

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Advances in controlled drug delivery to the sinonasal mucosa

Schilling, Andrea L., Cannon, Erin, Lee, Stella E., Wang, Eric W., Little, Steven R. · 2022 · Biomaterials

Abstract

Controlled drug delivery is a valuable strategy for increasing local therapeutic concentrations in a sustained manner, particularly in locations that are difficult to access. One such target is the sinonasal mucosa, which can be chronically inflamed in patients with rhinitis or rhinosinusitis resulting in diminished quality of life, significant healthcare expenses, and multiple co-morbidities. While numerous medical therapies with daily administration are available, anatomical, physiological, and patient adherence barriers can limit their therapeutic efficacy. As such, there has been considerable development of biomaterial-based systems that can locally deliver anti-inflammatory, antibiotic, decongestant, and antihistamine medications over an extended duration. This review aims to highlight advances in such biomaterial-based systems for sinonasal delivery. Delivery vehicles including nasal packs, dressings, sinus stents, polymeric meshes, nanoparticles, microparticles, and in situ hydrogels are reviewed. Benefits of these vehicles are discussed, as well as their limitations, which, recently, has motivated the development of combination systems that leverage desirable properties of their individual components to enhance therapeutic delivery. Finally, discussion is provided on the potential of combination delivery vehicles, which can provide greater control of the duration of therapeutic release, as well as the ability to encapsulate multiple therapies, provide mechanical support, or conform to the mucosa. The future clinical use of controlled release systems with these attributes could have a transformative impact on improving treatment of difficult-to-control chronic diseases of the sinonasal mucosa.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biomaterials.2022.121430

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 156

  1. Bhattacharyya, 2011, Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States, Ann. Otol. Rhinol. Laryngol., 120, 423, 10.1177/000348941112000701 · DOI · Paper page
  2. Meltzer, 2011, The economic impact of allergic rhinitis and current guidelines for treatment, Ann. Allergy Asthma Immunol., 106, S12, 10.1016/j.anai.2010.10.014 · DOI · Paper page
  3. Sahin-Yilmaz, 2011, Anatomy and physiology of the upper airway, Proc. Am. Thorac. Soc., 8, 31, 10.1513/pats.201007-050RN · DOI · Paper page
  4. Jones, 2001, The nose and paranasal sinuses physiology and anatomy, Adv. Drug Deliv. Rev., 51, 5, 10.1016/S0169-409X(01)00172-7 · DOI · Paper page
  5. Leal, 2017, Physicochemical properties of mucus and their impact on transmucosal drug delivery, Int. J. Pharm., 532, 555, 10.1016/j.ijpharm.2017.09.018 · DOI · Paper page
  6. Gizurarson, 2015, The effect of cilia and the mucociliary clearance on successful drug delivery, Biol. Pharm. Bull., 38, 497, 10.1248/bpb.b14-00398 · DOI
  7. Schwab, 1998, Filtration of particulates in the human nose, Laryngoscope, 108, 120, 10.1097/00005537-199801000-00023 · doi:10.1097/00005537-199801000-00023
  8. Dalgorf, 2013, Sinonasal anatomy and function, Am. J. Rhinol. Allergy, 27, S3, 10.2500/ajra.2013.27.3888 · doi:10.2500/ajra.2013.27.3888
  9. Parikh, 2014, Drug-eluting nasal implants: formulation, characterization, clinical applications and challenges, Pharm. Times, 6, 249
  10. Keck, 2000, Temperature profile in the nasal cavity, Laryngoscope, 110, 651, 10.1097/00005537-200004000-00021 · DOI · Paper page
  11. Pinto, 2011, Olfaction, Proc. Am. Thorac. Soc., 8, 46, 10.1513/pats.201005-035RN · DOI
  12. Mygind, 1998, Anatomy, physiology and function of the nasal cavities in health and disease, Adv. Drug Deliv. Rev., 29, 3, 10.1016/S0169-409X(97)00058-6 · DOI · Paper page
  13. Lai, 2009, Micro- and macrorheology of mucus, Adv. Drug Deliv. Rev., 61, 86, 10.1016/j.addr.2008.09.012 · DOI · Paper page
  14. Cohen, 2006, Sinonasal mucociliary clearance in health and disease, Ann. Otol. Rhinol. Laryngol., 115, 20, 10.1177/00034894061150S904 · DOI · Paper page
  15. Laulajainen-Hongisto, 2020, Airway epithelial dynamics in allergy and related chronic inflammatory airway diseases, Front. Cell Dev. Biol., 8, 204, 10.3389/fcell.2020.00204 · DOI
  16. Fokkens, 2000, Upper airway defence mechanisms, Paediatr. Respir. Rev., 1, 336
  17. Conway, 2000, The nose and nitric oxide: a review, Clin. Otolaryngol., 25, 337, 10.1046/j.1365-2273.2000.00378.x · DOI
  18. Bogdan, 2001, Nitric oxide and the immune response, Nat. Immunol., 2, 907, 10.1038/ni1001-907 · DOI · Paper page
  19. Runer, 1998, Effects of nitric oxide on blood flow and mucociliary activity in the human nose, Ann. Otol. Rhinol. Laryngol., 107, 40, 10.1177/000348949810700108 · DOI
  20. Brożek, 2017, Allergic rhinitis and its impact on asthma (ARIA) guidelines—2016 revision, J. Allergy Clin. Immunol., 140, 950, 10.1016/j.jaci.2017.03.050 · DOI · Paper page
  21. Bousquet, 2008, Allergic rhinitis and its impact on asthma (ARIA) 2008, Allergy, 63, 8, 10.1111/j.1398-9995.2007.01620.x · DOI · Paper page
  22. Dykewicz, 2010, Rhinitis and sinusitis, J. Allergy Clin. Immunol., 125, S103, 10.1016/j.jaci.2009.12.989 · DOI · Paper page
  23. DeConde, 2016, Chronic rhinosinusitis: epidemiology and burden of disease, Am. J. Rhinol. Allergy, 30, 134, 10.2500/ajra.2016.30.4297 · DOI · Paper page
  24. Baroody, 2000, Antiallergic effects of H1-receptor antagonists, Allergy, 55, 17, 10.1034/j.1398-9995.2000.00803.x · DOI
  25. Rosenfeld, 2015, Clinical practice guideline (update): adult sinusitis, Otolaryngol. Head Neck Surg., 152, S1
  26. Snidvongs, 2017, Update on intranasal medications in rhinosinusitis, Curr. Allergy Asthma Rep., 17, 47, 10.1007/s11882-017-0720-3 · DOI
  27. Piromchai, 2013, Chronic rhinosinusitis and emerging treatment options, Int. J. Gen Med., 6, 453, 10.2147/IJGM.S29977 · DOI
  28. Schleimer, 2017, Immunopathogenesis of chronic rhinosinusitis and nasal polyposis, Annu. Rev. Pathol., 12, 331, 10.1146/annurev-pathol-052016-100401 · DOI · Paper page
  29. Fastenberg, 2016, Biofilms in chronic rhinosinusitis: pathophysiology and therapeutic strategies, World J. Otorhinol. Head Neck Surg., 2, 219, 10.1016/j.wjorl.2016.03.002 · DOI · Paper page
  30. Hulse, 2015, Immune mechanisms of chronic rhinosinusitis, Curr. Allergy Asthma Rep., 16, 1, 10.1007/s11882-015-0579-0 · DOI
  31. Lee, 2011, Chronic rhinosinusitis as a multifactorial inflammatory disorder, Curr. Infect. Dis. Rep., 13, 159, 10.1007/s11908-011-0166-z · DOI
  32. Sastre, 2012, Local and systemic safety of intranasal corticosteroids, J Investig. Allergol. Clin. Immunol., 22, 1
  33. Han, 2012, Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis, Int. Forum Allergy Rhinol., 2, 271, 10.1002/alr.21044 · DOI
  34. DeConde, 2017, Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis, Laryngoscope, 127, 550, 10.1002/lary.26391 · DOI · Paper page
  35. Mendelsohn, 2011, Revision rates after endoscopic sinus surgery: a recurrence analysis, Ann. Otol. Rhinol. Laryngol., 120, 162, 10.1177/000348941112000304 · DOI · Paper page
  36. Möller, 2013, Topical drug delivery in chronic rhinosinusitis patients before and after sinus surgery using pulsating aerosols, PLoS One, 8, 10.1371/journal.pone.0074991 · DOI
  37. Harvey, 2008, Effects of endoscopic sinus surgery and delivery device on cadaver sinus irrigation, Otolaryngol. Head Neck Surg., 139, 137, 10.1016/j.otohns.2008.04.020 · DOI · Paper page
  38. Möller, 2014, Drug delivery to paranasal sinuses using pulsating aerosols, J. Aerosol Med. Pulm., 27, 255, 10.1089/jamp.2013.1071 · DOI
  39. Torres, 2019, Natural polysaccharide nanomaterials: an overview of their immunological properties, Int. J. Mol. Sci., 20, 5092, 10.3390/ijms20205092 · DOI · Paper page
  40. Klemm, 2005, Cellulose: fascinating biopolymer and sustainable raw material, Angew Chem. Int. Ed. Engl., 44, 3358, 10.1002/anie.200460587 · DOI · Paper page
  41. Massey, 2016, Biomaterials in rhinology, Otolaryngol. Head Neck Surg., 154, 606, 10.1177/0194599815627782 · doi:10.1177/0194599815627782
  42. Arca, 2018, Pharmaceutical applications of cellulose ethers and cellulose ether esters, Biomacromolecules, 19, 2351, 10.1021/acs.biomac.8b00517 · doi:10.1021/acs.biomac.8b00517
  43. Xu, 2012, Hyaluronic acid-based hydrogels: from a natural polysaccharide to complex networks, Soft Matter, 8, 3280, 10.1039/c2sm06463d · DOI · Paper page
  44. Casale, 2015, Hyaluronic acid: perspectives in upper aero-digestive tract. A systematic review, PLoS One, 10, 1, 10.1371/journal.pone.0130637 · DOI · Paper page
  45. Hwang, 2018, Randomized controlled trial of steroid-soaked absorbable calcium alginate nasal packing following endoscopic sinus surgery, Laryngoscope, 128, 311, 10.1002/lary.26871 · DOI
  46. Martău, 2019, The use of chitosan, alginate, and pectin in the biomedical and food sector-biocompatibility, bioadhesiveness, and biodegradability, Polym. Bull., 11, 1837
  47. Tønnesen, 2002, Alginate in drug delivery systems, Drug Dev. Ind. Pharm., 28, 621, 10.1081/DDC-120003853 · DOI · Paper page
  48. Abruzzo, 2019, Cromolyn-crosslinked chitosan nanoparticles for the treatment of allergic rhinitis, Eur. J. Pharmaceut. Sci., 131, 136, 10.1016/j.ejps.2019.02.015 · DOI
  49. Sun, 2019, Nasal adaptive chitosan-based nano-vehicles for anti-allergic drug delivery, Int. J. Biol. Macromol., 135, 1182, 10.1016/j.ijbiomac.2019.05.188 · DOI
  50. Pandey, 2016, Formulation and evaluation of levocetirizine loaded mucoadhesive microspheres for nasal delivery, Int. J. Pharma Sci. Res., 7, 2242
  51. Wang, 2020, Astragalus polysaccharides/chitosan microspheres for nasal delivery: preparation, optimization, characterization, and pharmacodynamics, Front. Pharmacol., 11, 230, 10.3389/fphar.2020.00230 · DOI
  52. Cao, 2015, Potential application of injectable chitosan hydrogel treated with siRNA in chronic rhinosinusitis therapy, Mol. Med. Rep., 12, 6688, 10.3892/mmr.2015.4237 · DOI
  53. Garakani, 2020, Fabrication of chitosan/polyvinylpyrrolidone hydrogel scaffolds containing PLGA microparticles loaded with dexamethasone for biomedical applications, Int. J. Biol. Macromol., 164, 356, 10.1016/j.ijbiomac.2020.07.138 · DOI
  54. Su, 2020, Chitosan hydrogel doped with PEG-PLA nanoparticles for the local delivery of miRNA-146a to treat allergic rhinitis, Pharm. Times, 12, 907
  55. Ways, 2018, Chitosan and its derivatives for application in mucoadhesive drug delivery systems, Polym. Bull., 10, 267
  56. England, 1999, Nasal pH measurement: a reliable and repeatable parameter, Clin. Otolaryngol. (Oxf.), 24, 67, 10.1046/j.1365-2273.1999.00223.x · DOI · Paper page
  57. Kim, 2013, Nasal pH in patients with chronic rhinosinusitis before and after endoscopic sinus surgery, Am. J. Otolaryngol., 34, 505, 10.1016/j.amjoto.2013.04.015 · DOI
  58. Cao, 2009, In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate, Int. J. Pharm., 365, 109, 10.1016/j.ijpharm.2008.08.042 · DOI
  59. Nižić, 2019, Innovative sprayable in situ gelling fluticasone suspension: development and optimization of nasal deposition, Int. J. Pharm., 563, 445, 10.1016/j.ijpharm.2019.04.015 · DOI
  60. Gohel, 2009, Preparation and evaluation of soft gellan gum gel containing paracetamol, Indian J. Pharmaceut. Sci., 71, 120, 10.4103/0250-474X.54273 · doi:10.4103/0250-474x.54273
  61. Bacelar, 2016, Recent progress in gellan gum hydrogels provided by functionalization strategies, J. Mater. Chem. B, 4, 6164, 10.1039/C6TB01488G · DOI · Paper page
  62. Thakur, 1997, Chemistry and uses of pectin — a review, Crit Rev Food Sci, 37, 47, 10.1080/10408399709527767 · DOI · Paper page
  63. Adriaensen, 2017, Safety and efficacy of a bioabsorbable fluticasone propionate–eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial, Int. Forum Allergy Rhinol., 7, 813, 10.1002/alr.21963 · doi:10.1002/alr.21963
  64. Sow, 2018, Pilot study comparing steroid-impregnated and non- steroid-impregnated absorbable nasal dressing following endoscopic sinus surgery, Med. J. Malaysia, 73, 244
  65. Rajangam, 2013, Fibrinogen and fibrin based micro and nano scaffolds incorporated with drugs, proteins, cells and genes for therapeutic biomedical applications, Int. J. Nanomed., 8, 3641
  66. Weisel, 2017, Fibrin formation, structure and properties, Subcell. Biochem., 82, 405, 10.1007/978-3-319-49674-0_13 · DOI · Paper page
  67. Catoira, 2019, Overview of natural hydrogels for regenerative medicine applications, J. Mater. Sci. Mater. Med., 30, 115, 10.1007/s10856-019-6318-7 · DOI · Paper page
  68. Tyler, 2016, Polylactic acid (PLA) controlled delivery carriers for biomedical applications, Adv. Drug Deliv. Rev., 107, 163, 10.1016/j.addr.2016.06.018 · DOI · Paper page
  69. Anderson, 2012, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev., 64, 72, 10.1016/j.addr.2012.09.004 · DOI · Paper page
  70. Rothstein, 2009, A unified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices, Biomaterials, 30, 1657, 10.1016/j.biomaterials.2008.12.002 · DOI · Paper page
  71. Rothstein, 2011, A “tool box” for rational design of degradable controlled release formulations, J. Mater. Chem., 21, 29, 10.1039/C0JM01668C · DOI
  72. Seyednejad, 2011, Functional aliphatic polyesters for biomedical and pharmaceutical applications, J. Contr. Release, 152, 168, 10.1016/j.jconrel.2010.12.016 · DOI · Paper page
  73. Dash, 2012, Poly-є-caprolactone based formulations for drug delivery and tissue engineering: a review, J. Contr. Release, 158, 15, 10.1016/j.jconrel.2011.09.064 · DOI · Paper page
  74. Sharma, 2018, The development of bioresorbable composite polymeric implants with high mechanical strength, Nat. Mater., 17, 96, 10.1038/nmat5016 · DOI · Paper page
  75. Herzberger, 2016, Polymerization of ethylene oxide, propylene oxide, and other alkylene oxides: synthesis, novel polymer architectures, and bioconjugation, Chem. Rev., 116, 2170, 10.1021/acs.chemrev.5b00441 · DOI · Paper page
  76. Knop, 2010, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew Chem. Int. Ed. Engl., 49, 6288, 10.1002/anie.200902672 · DOI · Paper page
  77. Lin, 2009, PEG hydrogels for the controlled release of biomolecules in regenerative medicine, Pharmaceut. Res., 26, 631, 10.1007/s11095-008-9801-2 · DOI · Paper page
  78. Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Deliv. Rev., 61, 158, 10.1016/j.addr.2008.11.002 · DOI · Paper page
  79. Giuliano, 2018, Mucosal applications of poloxamer 407-based hydrogels: an overview, Pharm. Times, 10, 159
  80. Russo, 2019, Poloxamer hydrogels for biomedical applications, Pharm. Times, 11, 671
  81. Bellotti, 2019, Tuning of thermoresponsive pNIPAAm hydrogels for the topical retention of controlled release ocular therapeutics, J. Mater. Chem. B, 7, 1276, 10.1039/C8TB02976H · DOI
  82. Klouda, 2008, Thermoresponsive hydrogels in biomedical applications, Eur. J. Pharm. Biopharm., 68, 34, 10.1016/j.ejpb.2007.02.025 · DOI · Paper page
  83. Lanzalaco, 2017, Poly(N-isopropylacrylamide) and copolymers: a review on recent progresses in biomedical applications, Prog. Colloid Polym. Sci. S, 3, 36
  84. Cherng, 2013, Polyurethane-based drug delivery systems, Int. J. Pharm., 450, 145, 10.1016/j.ijpharm.2013.04.063 · DOI · Paper page
  85. Shi, 2009, Recent advances in synthetic bioelastomers, Int. J. Mol. Sci., 10, 4223, 10.3390/ijms10104223 · DOI
  86. Baker, 2012, A review of polyvinyl alcohol and its uses in cartilage and orthopedic applications, J. Biomed. Mater. Res. B Appl. Biomater., 100B, 1451, 10.1002/jbm.b.32694 · DOI · Paper page
  87. Franco, 2020, The use of poly(N-vinyl pyrrolidone) in the delivery of drugs: a review, Polym. Bull., 12, 1114
  88. Ludmila, 2017, PVP based materials: biodegradation in different environments, Ecol. Chem. Eng., 24, 299
  89. Attama, 2016, Functional performance of chitosan/carbopol 974P NF matrices in captopril tablets, J. Pharm. (Lahore), 2016, 3240290
  90. Poscher, 2020, Trends in degradable mesoporous organosilica-based nanomaterials for controlling drug delivery: a mini review, Materials, 13, 3668, 10.3390/ma13173668 · DOI
  91. Jaganathan, 2012, Biocompatibility assessment of Si-based nano- and micro-particles, Adv. Drug Deliv. Rev., 64, 1800, 10.1016/j.addr.2012.05.008 · DOI
  92. Dkhar, 2018, Intranasal drug delivery devices and interventions associated with post-operative endoscopic sinus surgery, Pharmaceut. Dev. Technol., 23, 282, 10.1080/10837450.2017.1389956 · DOI
  93. Szczygielski, 2010, Use of CMC foam sinus dressing in FESS, Eur. Arch. Oto-Rhino-Laryngol., 267, 537, 10.1007/s00405-009-1117-2 · DOI
  94. Rudmik, 2012, Effect of a dexamethasone Sinu-FoamTM middle meatal spacer on endoscopic sinus surgery outcomes: a randomized, double-blind, placebo-controlled trial, Int. Forum Allergy Rhinol., 2, 248, 10.1002/alr.21011 · doi:10.1002/alr.21011
  95. Patel, 2017, Biocompatibility and pharmacokinetics of fluticasone-eluting sinus implant in a rabbit model, Am. J. Rhinol. Allergy, 31, 382, 10.2500/ajra.2017.31.4481 · doi:10.2500/ajra.2017.31.4481
  96. Xu, 2016, Absorbable steroid-impregnated spacer after endoscopic sinus surgery to reduce synechiae formation, Ann. Otol. Rhinol. Laryngol., 125, 195, 10.1177/0003489415606446 · DOI
  97. Côté, 2010, Triamcinolone-impregnated nasal dressing following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study, Laryngoscope, 120, 1269, 10.1002/lary.20905 · doi:10.1002/lary.20905
  98. Dautremont, 2014, The role of immediate postoperative systemic corticosteroids when utilizing a steroid-eluting spacer following sinus surgery, Otolaryngol. Head Neck Surg., 150, 689, 10.1177/0194599814521373 · DOI
  99. Zhao, 2018, Effects of mometasone furoate–impregnated biodegradable nasal dressing on endoscopic appearance in healing process following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study, Int. Forum Allergy Rhinol., 8, 1233, 10.1002/alr.22213 · doi:10.1002/alr.22213
  100. Sabarinath, 2017, Triamcinolone impregnated nasal pack in endoscopic sinus surgery: our experience, Indian J. Otolaryngol., 69, 88, 10.1007/s12070-016-1041-x · DOI
  101. Zhao, 2013, A systematic review of nonabsorbable, absorbable, and steroid-impregnated spacers following endoscopic sinus surgery, Int. Forum Allergy Rhinol., 3, 896, 10.1002/alr.21201 · doi:10.1002/alr.21201
  102. Wang, 2014, Merocel versus nasopore for nasal packing: a meta-analysis of randomized controlled trials, PLoS One, 9
  103. Li, 2019, Efficacy and safety of steroid-impregnated implants following sinus surgery: a meta-analysis, Laryngoscope, 130, 2754, 10.1002/lary.28388 · DOI
  104. Maccabee, 2003, Effects of topically applied biomaterials on paranasal sinus mucosal healing, Am. J. Rhinol. Allergy, 17, 203, 10.1177/194589240301700405 · doi:10.1177/194589240301700405
  105. Orlandi, 2004, Is nasal packing necessary following endoscopic sinus surgery?, Laryngoscope, 114, 1541, 10.1097/00005537-200409000-00007 · DOI
  106. Wei, 2012, Mometasone implant for chronic rhinosinusitis, Med. Devices, 5, 75
  107. Han, 2019, Topical therapies for management of chronic rhinosinusitis: steroid implants, Int. Forum Allergy Rhinol., 9, S22, 10.1002/alr.22344 · doi:10.1002/alr.22344
  108. Shen, 2018, Mometasone furoate sinus implant – a new targeted approach to treating recurrent nasal polyp disease, Expet Rev. Clin. Pharmacol., 11, 1163, 10.1080/17512433.2018.1549485 · doi:10.1080/17512433.2018.1549485
  109. Murr, 2011, Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent, Int. Forum Allergy Rhinol., 1, 23, 10.1002/alr.20020 · DOI · Paper page
  110. Han, 2014, RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis, Int. Forum Allergy Rhinol., 4, 861, 10.1002/alr.21426 · DOI
  111. Santarelli, 2016, Evaluation of the PROPEL® mini sinus implant for the treatment of frontal sinus disease, Expet Opin. Drug Deliv., 13, 1789, 10.1080/17425247.2016.1250740 · doi:10.1080/17425247.2016.1250740
  112. Smith, 2016, Randomized controlled trial of a bioabsorbable steroid-releasing implant in the frontal sinus opening, Laryngoscope, 126, 2659, 10.1002/lary.26140 · DOI
  113. Luong, 2018, Safety and effectiveness of a bioabsorbable steroid-releasing implant for the paranasal sinus ostia: a randomized clinical trial, JAMA Otolaryngol Head Neck Surg, 144, 28
  114. Matheny, 2014, Safety, feasibility, and efficacy of placement of steroid-eluting bioabsorbable sinus implants in the office setting: a prospective case series, Int. Forum Allergy Rhinol., 4, 808, 10.1002/alr.21416 · DOI
  115. Forwith, 2011, ADVANCE: a multisite trial of bioabsorbable steroid-eluting sinus implants, Laryngoscope, 121, 2473, 10.1002/lary.22228 · DOI
  116. Kern, 2018, A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps, Int. Forum Allergy Rhinol., 8, 471, 10.1002/alr.22084 · DOI
  117. Forwith, 2016, RESOLVE: bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis after sinus surgery: 6-month outcomes from a randomized, controlled, blinded study, Int. Forum Allergy Rhinol., 6, 573, 10.1002/alr.21741 · DOI
  118. Cho, 2017, Tolerance and pharmacokinetics of a ciprofloxacin-coated sinus stent in a preclinical model, Int. Forum Allergy Rhinol., 7, 352, 10.1002/alr.21892 · DOI
  119. Cho, 2018, Preclinical therapeutic efficacy of the ciprofloxacin-eluting sinus stent for Pseudomonas aeruginosa sinusitis, Int. Forum Allergy Rhinol., 8, 482, 10.1002/alr.22081 · DOI
  120. Douglas, 2019, Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis, Int. Forum Allergy Rhinol., 9, 378, 10.1002/alr.22288 · DOI
  121. Marple, 2012, Advance II: a prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants, Otolaryngol. Head Neck Surg., 146, 1004, 10.1177/0194599811435968 · DOI
  122. Lavigne, 2014, Steroid-eluting sinus implant for in-office treatment of recurrent nasal polyposis: a prospective, multicenter study, Int. Forum Allergy Rhinol., 4, 381, 10.1002/alr.21309 · DOI
  123. Al-Halifa, 2019, Nanoparticle-based vaccines against respiratory viruses, Front. Immunol., 10, 22, 10.3389/fimmu.2019.00022 · DOI · Paper page
  124. Far, 2020, Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery, ACS Omega, 5, 7432, 10.1021/acsomega.0c00111 · doi:10.1021/acsomega.0c00111
  125. Sallam, 2016, Rationally designed nanocarriers for intranasal therapy of allergic rhinitis: influence of carrier type on in vivo nasal deposition, Int. J. Nanomed., 11, 2345, 10.2147/IJN.S98547 · DOI
  126. Lai, 2011, Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus, Biomaterials, 32, 6285, 10.1016/j.biomaterials.2011.05.008 · DOI
  127. Lee, 2017, Sinonasal delivery of resveratrol via mucoadhesive nanostructured microparticles in a nasal polyp mouse model, Sci Rep-Uk, 7, 40249, 10.1038/srep40249 · DOI
  128. Zheng, 2020, A review of the pharmacological action of Astragalus polysaccharide, Front. Pharmacol., 11, 349, 10.3389/fphar.2020.00349 · doi:10.3389/fphar.2020.00349
  129. Kim, 2014, Budesonide/cyclodextrin complex-loaded lyophilized microparticles for intranasal application, Drug Dev. Ind. Pharm., 40, 743, 10.3109/03639045.2013.782503 · DOI
  130. Shi, 2016, The effects of mPEG proportion and LA/GA ratio on degradation and drug release behaviors of PLGA-mPEG microparticles, Pharmazie, 71, 243
  131. Abuzeid, 2018, Nitric oxide-releasing microparticles as a potent antimicrobial therapeutic against chronic rhinosinusitis bacterial isolates, Int. Forum Allergy Rhinol., 8, 1190, 10.1002/alr.22185 · DOI
  132. Yang, 2020, Novel nitric oxide‒generating platform using manuka honey as an anti-biofilm strategy in chronic rhinosinusitis, International Forum of Allergy & Rhinology, 10, 223, 10.1002/alr.22472 · DOI
  133. Lai, 2011, Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus, Biomaterials, 32, 6285, 10.1016/j.biomaterials.2011.05.008 · DOI
  134. Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Deliv. Rev., 61, 158, 10.1016/j.addr.2008.11.002 · DOI · Paper page
  135. Kammona, 2012, Recent advances in nanocarrier-based mucosal delivery of biomolecules, J. Contr. Release, 161, 781, 10.1016/j.jconrel.2012.05.040 · DOI
  136. Mahdi, 2015, Development of mucoadhesive sprayable gellan gum fluid gels, Int. J. Pharm., 488, 12, 10.1016/j.ijpharm.2015.04.011 · DOI
  137. Altuntaş, 2017, Formulation and evaluation of thermoreversible in situ nasal gels containing mometasone furoate for allergic rhinitis, AAPS PharmSciTech, 18, 2673, 10.1208/s12249-017-0747-8 · doi:10.1208/s12249-017-0747-8
  138. Karavasili, 2016, Smart materials: in situ gel-forming systems for nasal delivery, Drug Discov. Today, 21, 157, 10.1016/j.drudis.2015.10.016 · DOI · Paper page
  139. Agrawal, 2020, Stimuli-responsive in situ gelling system for nose-to-brain drug delivery, J. Contr. Release, 327, 235, 10.1016/j.jconrel.2020.07.044 · DOI · Paper page
  140. Bellotti, 2021, Injectable thermoresponsive hydrogels as drug delivery system for the treatment of central nervous system disorders: a review, J. Contr. Release, 329, 16, 10.1016/j.jconrel.2020.11.049 · DOI · Paper page
  141. Altuntaş, 2018, Effects of a thermosensitive in situ gel containing mometasone furoate on a rat allergic rhinitis model, Am. J. Rhinol. Allergy, 32, 132, 10.1177/1945892418764951 · doi:10.1177/1945892418764951
  142. Aksoy, 2017, Effect of a combination of mometasone furoate, levofloxacin, and retinyl palmitate with an in situ gel-forming nasal delivery system on nasal mucosa damage repair in an experimental rabbit model, Biomed. Pharmacother., 96, 603, 10.1016/j.biopha.2017.10.023 · DOI
  143. Pandey, 2017, Formulation, functional evaluation and ex vivo performance of thermoresponsive soluble gels - a platform for therapeutic delivery to mucosal sinus tissue, Eur. J. Pharmaceut. Sci., 96, 499, 10.1016/j.ejps.2016.10.017 · DOI
  144. Chu, 2013, Preparation of a paeonol-containing temperature-sensitive in situ gel and its preliminary efficacy on allergic rhinitis, Int. J. Mol. Sci., 14, 6499, 10.3390/ijms14036499 · doi:10.3390/ijms14036499
  145. Cho, 2019, In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against Pseudomonas aeruginosa biofilms, Int. Forum Allergy Rhinol., 9, 486, 10.1002/alr.22285 · doi:10.1002/alr.22285
  146. Lim, 2020, Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis, Int. Forum Allergy Rhinol., 10, 481, 10.1002/alr.22514 · DOI
  147. Chen, 2020, Injectable and self-healing hydrogel with anti-bacterial and anti-inflammatory properties for acute bacterial rhinosinusitis with micro invasive treatment, Adv Healthc Mater, 9, 2001032, 10.1002/adhm.202001032 · DOI
  148. Schilling, 2021, A thermoresponsive hydrogel system for long-acting corticosteroid delivery into the paranasal sinuses, J. Contr. Release, 330, 889, 10.1016/j.jconrel.2020.10.062 · DOI · Paper page
  149. Gadkaree, 2019, Use of corticosteroid-eluting sinus stents between 2012 and 2017, JAMA Otolaryngol Head Neck Surg, 145, 90, 10.1001/jamaoto.2018.2944 · doi:10.1001/jamaoto.2018.2944
  150. Rudmik, 2014, Economic evaluation of a steroid-eluting sinus implant following endoscopic sinus surgery for chronic rhinosinusitis, Otolaryngol. Head Neck Surg., 151, 359, 10.1177/0194599814533779 · DOI
  151. Li, 2020, Design of biodegradable, implantable devices towards clinical translation, Nat. Rev. Mater., 5, 61, 10.1038/s41578-019-0150-z · DOI · Paper page
  152. Salade, 2019, How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods, Int. J. Pharm., 561, 47, 10.1016/j.ijpharm.2019.02.026 · DOI
  153. Al-Sayed, 2017, Models for the study of nasal and sinus physiology in health and disease: a review of the literature, Laryngoscope Investig Otolaryngol, 2, 398, 10.1002/lio2.117 · DOI
  154. Schilling, 2021, Evaluating inflammation in an obstruction-based chronic rhinosinusitis model in rabbits, Int. Forum Allergy Rhinol., 11, 807, 10.1002/alr.22729 · doi:10.1002/alr.22729
  155. Cho, 2020, A preclinical model to tackle chronic rhinosinusitis, Int. Forum Allergy Rhinol.
  156. Schilling, 2021, Reply: a preclinical model to tackle chronic rhinosinusitis, Int. Forum Allergy Rhinol., 11, 828, 10.1002/alr.22769 · doi:10.1002/alr.22769

Cited by

See all 30

Metadata

Authors
Schilling, A. L., Cannon, E., Lee, S. E., Wang, E. W., & Little, S. R.
Venue
Biomaterials
Publisher
Elsevier BV
Published
2022-03
Volume
282
Pages
121430
ISSN
0142-9612
Cited by
30
References
6
Language
en
Funders
Eye and Ear Foundation of Pittsburgh

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in controlled drug delivery to the sinonasal mucosa. https://app.cochat.ai/papers/10.1016/j.biomaterials.2022.121430
The paper
Schilling, A. L., Cannon, E., Lee, S. E., Wang, E. W., & Little, S. R. (2022). Advances in controlled drug delivery to the sinonasal mucosa. Biomaterials. https://doi.org/10.1016/j.biomaterials.2022.121430

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.